Q-omics provides the consensus-scored MIR181B2 profile across patient tissues and cancer cell-line models. MIR181B2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR181B2 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, MIR181B2 RNA expression shows 14,463 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, STAD, and GBM as cancer lineages where MIR181B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR181B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR181B2 survival associations across molecular data types. MIR181B2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR181B2 RNA expression–survival associations across cancer types. High MIR181B2 expression shows unfavorable associations in MESO, KICH, LIHC, READ and PCPG, but favorable associations in STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR181B2 RNA expression.
This table summarizes MIR181B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR181B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR181B2 shows higher tumor expression in STAD, THCA and HNSC. The STAD box plot shows higher MIR181B2 RNA expression in tumor versus normal tissue (log2 FC = +0.408, t-test p = .029).
This table shows molecular features associated with MIR181B2 in patient tissues and cancer cell lines. In patient samples, MIR181B2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
